Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.

Jana de BonifaceMatilda AppelgrenRobert SzulkinSara AlknerYvette AnderssonLeif BergkvistJan FrisellOreste Davide GentiliniMichalis KontosThorsten KühnDan LundstedtBirgitte Vrou OffersenRoger Olofsson BaggeToralf ReimerMalin SundPeer ChristiansenLisa RydénTove Filtenborg Tvedskovnull null

Published in: The Lancet. Oncology (2024)

Swedish Research Council, the Swedish Cancer Society, the Nordic Cancer Union, and the Swedish Breast Cancer Association.

Keyphrases

papillary thyroid
lymph node
clinical trial
squamous cell
study protocol
sentinel lymph node
early stage
open label
prostate cancer
rectal cancer
phase iii
lymph node metastasis
neoadjuvant chemotherapy
double blind
ultrasound guided
cell proliferation
phase ii
combination therapy
minimally invasive